824 related articles for article (PubMed ID: 32314085)
1. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
[TBL] [Abstract][Full Text] [Related]
2. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
[TBL] [Abstract][Full Text] [Related]
3. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
4. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
5. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
[No Abstract] [Full Text] [Related]
6. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
7. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
Luo Y; Bai R; Zhang W; Qin G
Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Arbel R; Aboalhasan E; Hammerman A; Azuri J
Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
11. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapié CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Jüni P
J Am Heart Assoc; 2021 Sep; 10(18):e019918. PubMed ID: 34514812
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
15. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
Kanbay M; Tapoi L; Ureche C; Tanriover C; Cevik E; Demiray A; Afsar B; Cherney DZI; Covic A
Int Urol Nephrol; 2022 Apr; 54(4):827-841. PubMed ID: 34273060
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
Qiu M; Ding LL; Zhou HR
Am J Cardiovasc Drugs; 2022 Jan; 22(1):69-81. PubMed ID: 34231123
[TBL] [Abstract][Full Text] [Related]
17. Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
Jiang Y; Yang P; Fu L; Sun L; Shen W; Wu Q
Front Endocrinol (Lausanne); 2022; 13():802992. PubMed ID: 35370961
[TBL] [Abstract][Full Text] [Related]
18. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y
Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550
[TBL] [Abstract][Full Text] [Related]
20. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
